Drug intelligence / Profile preview

BCWP-C012

Development stage: Preclinical
Lead developer: BC World Pharm
Modality: Small Molecules

Overview

BCWP-C012 is a preclinical-stage small molecule drug candidate developed by BCWorld Pharma for the treatment of cardiovascular disease. It is classified as an "improved new drug" (개량신약), a regulatory category in South Korea for drugs that offer improvements in safety, efficacy, or usefulness over existing products through modifications in chemical structure, formulation, or route of administration. As of 2024, the specific active pharmaceutical ingredient and mechanism of action remain proprietary to the developer.

Beyond the preview

Go deeper on BCWP-C012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCWP-C012.

Explore the full profile